First-Line Hepatic Arterial Infusion Chemotherapy Plus Immune Checkpoint Inhibitors Versus Systemic Chemotherapy Plus Immune Checkpoint Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
This retrospective study demonstrates that first-line hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors significantly improves overall survival, progression-free survival, and tumor reduction compared to systemic chemotherapy plus immune checkpoint inhibitors in patients with unresectable intrahepatic cholangiocarcinoma.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer that starts in the liver's bile ducts, known as intrahepatic cholangiocarcinoma, is a particularly stubborn disease. By the time it is found, it has often grown too large or spread too far to be removed with surgery. For years, the standard approach for these patients has been to pump chemotherapy drugs through the bloodstream, hoping they reach the tumor. Recently, doctors have added a new class of drugs called immune checkpoint inhibitors to this mix. These drugs do not kill cancer directly; instead, they take the brakes off the body's own immune system, allowing white blood cells to recognize and attack the tumor. While this combination has helped some patients, the results have been modest, and the cancer often returns or continues to grow inside the liver. The central challenge remains: how to deliver a stronger attack directly to the liver without overwhelming the rest of the body.
Researchers at the Third Affiliated Hospital of Harbin Medical University set out to test a different strategy for patients who cannot undergo surgery. Instead of relying solely on the bloodstream to deliver chemotherapy, they tried a method called hepatic arterial infusion chemotherapy. This approach uses a catheter to inject the drugs directly into the artery that feeds the liver tumor. Because liver tumors get most of their blood supply from this specific artery, the drugs hit the cancer at a much higher concentration right where it is growing, while exposing the rest of the body to less of the medication. The team wanted to see if combining this direct delivery method with immune checkpoint inhibitors would work better than the standard approach of giving both treatments through a vein in the arm.
To find the answer, the researchers looked back at medical records from 90 patients treated between August 2022 and September 2025. These patients all had unresectable intrahepatic cholangiocarcinoma and had received their first round of treatment with either the direct liver infusion method or the standard vein method, both paired with immune therapy. To ensure a fair comparison, the scientists used a statistical technique to match patients from the two groups so that factors like age, tumor size, and overall health were nearly identical. This allowed them to isolate the effect of the treatment method itself.
The results showed an advantage for the group receiving the direct liver infusion. Patients treated with the infusion method lived longer overall. On average, they survived for 603 days, compared to 387 days for those who received the standard vein treatment. They also went longer without their cancer getting worse. The median time before the disease progressed was 337 days for the infusion group, versus 200 days for the standard group. When the researchers looked at the tumors themselves, they found that the infusion method shrank the living part of the cancer more effectively. The tumors in the infusion group shrank by an average of 27 percent, while those in the standard group shrank by only 16 percent.
The study also examined safety. The direct infusion method did cause more frequent spikes in liver enzymes and bilirubin, which are markers of liver stress, and slightly more cases of high blood pressure. However, it caused fewer drops in white blood cell counts, which are a common side effect of standard chemotherapy. Crucially, no patients died from the treatment itself in either group. The researchers noted that the benefits of the infusion method were most noticeable in patients who had good overall health, no spread of cancer to other parts of the body, and tumors that were primarily located within the liver.
While the study was limited by its retrospective nature and the fact that it was conducted at a single hospital, and while residual confounding cannot be excluded, the data suggests that delivering chemotherapy directly to the liver artery, alongside immune therapy, may represent a feasible first-line treatment option for specific patients. The findings indicate that for those with unresectable liver cancer, intensifying the attack directly at the tumor site can extend life and delay disease progression, provided the patient's liver function is strong enough to handle the treatment. This approach does not replace the need for systemic drugs but appears to offer a more powerful way to control the disease where it is most active.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.